XtalPi

XtalPi, established in 2014, is a leading biotech firm leveraging artificial intelligence and advanced computing to accelerate new drug development. The company employs sophisticated algorithms to predict the precise crystal forms of drug compounds, a critical capability for its collaborations with pharmaceutical partners. This predictive power facilitates the creation of novel drugs and the generation of intellectual property, positioning XtalPi at the forefront of biopharmaceutical innovation. Operating from China, the company contributes significantly to the global R&D landscape.

With an employee range of 1,000-5,000 individuals and operations spanning 4 locations, XtalPi demonstrates substantial operational scale. Its integrated technology platform is designed to support biopharmaceutical clients throughout the entire drug discovery and development lifecycle, from initial research to process development. The company's commitment to scientific advancement is reflected in its team's expertise. For detailed information on the personnel driving these innovations, one can explore Meet XtalPi's team. This focus on human capital complements their technological prowess in addressing complex therapeutic challenges.

XtalPi has successfully secured significant funding rounds, including Series A ($5M), Series B ($61M), Series C ($318.8M), and Series D ($400M), accumulating over $784 million. This substantial financial backing underscores investor confidence in its AI-driven drug discovery model. The company's revenue stands at $117.7M, reflecting its market traction and the value of its technology platform. Investors and partners can Explore financial highlights for a deeper understanding of its economic performance and growth trajectory.